Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has added 22 new clinical and pre-clinical research projects through the acquisition of APIRx Pharmaceuticals.
Highlights: Positive phase 2a clinical trial results for IHL-42X with 60% of trial participants experiencing at least a 55% reduction in the Apnoea Hypopnea.
Incannex Healthcare (ASX: IHL) has announced it will acquire APIRx Pharmaceutical USA in an all scrip (share consideration) deal to affirm its position as a global leader in the fields of cannabinoid, psychedelic and combination pharmaceuticals.